<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25522" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Naproxen</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brutzkus</surname>
            <given-names>Joseph C.</given-names>
          </name>
          <aff>Un of Illinois at Chicago College of Med</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shahrokhi </surname>
            <given-names>Mahsa</given-names>
          </name>
          <aff>Saint James School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Varacallo</surname>
            <given-names>Matthew</given-names>
          </name>
          <aff>Penn Highlands Healthcare System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joseph Brutzkus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mahsa Shahrokhi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Varacallo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25522.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Naproxen is FDA-approved for treating acute gout, ankylosing spondylitis, bursitis, polyarticular juvenile idiopathic arthritis, osteoarthritis, tendonitis, rheumatoid arthritis, pain, and primary dysmenorrhea. It is the first-line treatment for acute gouty arthritis, osteoarthritis, musculoskeletal pain, inflammation, and dysmenorrhea. While naproxen and other NSAIDs are approved for the treatment of inflammatory arthropathies such as rheumatoid arthritis and ankylosing spondylitis, they do not alter the course of the disease, nor do they prevent joint and soft tissue destruction that are common sequelae of these diseases. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity of naproxen, so providers can direct patient therapy to optimal outcomes when pain relief is needed.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describes the mechanisms of action of naproxen.</p></list-item><list-item><p>Identify the approved and off-label indications for initiating therapy with naproxen.</p></list-item><list-item><p>Summarize the adverse event profile of naproxen.</p></list-item><list-item><p>Review the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients who can benefit from therapy with naproxen.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25522&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25522">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25522.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Naproxen was initially approved in 1976 for prescription use and remained a prescription drug until it received approval as an over-the-counter (OTC) medication in 1994. Naproxen has been FDA-approved to treat acute gout, ankylosing spondylitis, bursitis, polyarticular juvenile idiopathic arthritis, osteoarthritis, tendonitis, rheumatoid arthritis, pain, and primary dysmenorrhea. It is considered the first-line treatment for acute gouty arthritis, osteoarthritis, musculoskeletal pain, inflammation, and dysmenorrhea. While Naproxen and other NSAIDs have FDA approval for the treatment of inflammatory arthropathies, such as rheumatoid arthritis and ankylosing spondylitis, they do not alter the course of the disease, nor do they prevent joint and soft tissue destruction that are common sequelae of these diseases. In these cases, disease-modifying anti-rheumatic drugs (DMARDs) have become the first-line treatment for inflammatory arthropathies, and NSAIDs such as naproxen are used as adjunctive therapy.<xref ref-type="bibr" rid="article-25522.r1">[1]</xref><xref ref-type="bibr" rid="article-25522.r2">[2]</xref></p>
        <p>Off-label uses of naproxen include treating acute migraines and migraine prophylaxis, with Naproxen being considered a first-line abortive remedy for acute migraines. Further, it can be used for chronic migraine prevention as well, along with other medications such as beta-blockers, anti-depressants, and anticonvulsants.<xref ref-type="bibr" rid="article-25522.r3">[3]</xref></p>
      </sec>
      <sec id="article-25522.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Naproxen blocks arachidonate binding to competitively inhibit both cyclooxygenase (COX) isoenzymes, COX-1 and COX-2, resulting in analgesic and anti-inflammatory effects. COX-1 and COX-2 are catalysts of arachidonic acid conversion to prostaglandin G (PGG), the first step of the synthesis of prostaglandins and thromboxanes involved in rapid physiological responses. COX-1 is constitutively expressed in most tissues, while COX-2 is only expressed in the brain, kidney, bones, reproductive organs, and select tumors such as colon and prostate cancers. COX-1 is responsible for prostaglandin synthesis in response to stimulation by circulating hormones and maintaining healthy renal function, gastric mucosal integrity, and hemostasis. COX-2 is inducible in many cells in response to specific mediators of inflammation (e.g., interleukin-1, tumor necrosis factor, lipopolysaccharide).</p>
        <p>The anti-inflammatory mechanism of naproxen is due to decreased prostaglandin synthesis by inhibiting COX-1 and COX-2. The majority of anti-inflammation that Naproxen induces is mostly due to inhibition of the COX-2 isoenzyme; though, it should be noted that COX-1 is also expressed at distinct inflammatory sites. Further, COX-1 is also expressed in the joints of patients with rheumatoid arthritis or osteoarthritis, especially in the synovial lining. Therefore, although Naproxen targets both COX-1 and COX2, it is slightly more selective for the former. Additionally, naproxen is most effective in the setting of pain receptor sensitivity. It appears prostaglandins, specifically prostaglandins E and F, are responsible for sensitizing these pain receptors; therefore, naproxen has an additional, indirect analgesic effect by inhibiting further prostaglandin production.<xref ref-type="bibr" rid="article-25522.r4">[4]</xref></p>
        <p>The liver extensively metabolizes naproxen, and about 95% of the drug is excreted in the urine. Naproxen also has a half-life of 12 to 17 hours.</p>
      </sec>
      <sec id="article-25522.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Naproxen can be administered orally, in both immediate and extended-release tablets or suspension forms, or topically. Naproxen may be&#x000a0;taken&#x000a0;orally with food, milk, antacids&#x000a0;(preferably aluminum and magnesium hydroxide-containing antacids), proton pump inhibitors (PPI), or misoprostol to decrease the incidence of GI adverse effects.<xref ref-type="bibr" rid="article-25522.r5">[5]</xref> Naproxen sodium&#x000a0;is the most readily available form, and it has demonstrated a faster absorption compared to naproxen.</p>
        <p>As a rule, treatment with naproxen, as well as all NSAIDs, begins with the lowest effective dose for the shortest possible&#x000a0;duration. Also, consider starting with a&#x000a0;lower dose in geriatric patients due to the likelihood that the patient has comorbidities such as cardiovascular disease, chronic kidney disease, or history of GI ulcer/bleeding that increase the risk of adverse effects from NSAID therapy.</p>
        <p>
<italic toggle="yes">Specific dosing recommendations and treatment durations:</italic>
</p>
        <p>
<bold>Mild to Moderate Arthritis (osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>220 to 550 mg PO&#x000a0;every 12 hours</p>
          </list-item>
          <list-item>
            <p>Take with food if GI upset occurs</p>
          </list-item>
          <list-item>
            <p>Max: 1650 mg daily for up to 6 months</p>
          </list-item>
        </list>
        <p>
<bold>Acute Gouty Arthritis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>825 mg PO once, followed by 275 mg PO every 8 hours until symptom resolution</p>
          </list-item>
          <list-item>
            <p>Take with food if GI upset occurs</p>
          </list-item>
        </list>
        <p>
<bold>Acute Severe Headache or Migraine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Controversial concerning isolated naproxen sodium use in patients suffering from acute migraines.</p>
          </list-item>
          <list-item>
            <p>Naproxen sodium has a longer half-life&#x000a0;compared to other NSAID options, but headache relief rates at 2 hours after initial treatment are lower&#x000a0;than ibuprofen.<xref ref-type="bibr" rid="article-25522.r6">[6]</xref><xref ref-type="bibr" rid="article-25522.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Naproxen sodium dosing recommendations: 550 mg every 12 hours; can increase the dosage&#x000a0;to 825mg PO if needed; do not exceed the max of 1375 mg daily.</p>
          </list-item>
        </list>
        <p>
<bold>Maximum Recommended Daily Doses for Children</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>12 years and older<italic toggle="yes">&#x000a0;-&#x000a0;</italic>20 mg/kg/day by mouth, not to exceed 1000 mg/day by mouth; for non-prescription use, 660 mg/day by mouth</p>
          </list-item>
          <list-item>
            <p>2 to 12 years - 20 mg/kg/day by mouth, not to exceed 1000 mg/day by mouth. Non-prescription use is not recommended</p>
          </list-item>
          <list-item>
            <p>Less than 2 years - Safety and efficacy remain not established</p>
          </list-item>
        </list>
        <p>
<bold>Patients with Hepatic Impairment Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Although specific guidelines are not available,&#x000a0;caution is advised with respect to dosing; utilize the lowest recommended dosing regimen initially.</p>
          </list-item>
        </list>
        <p>
<bold>Patients with Renal Impairment Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>If creatinine clearance (CrCl) is greater than or equal to 30 mL/minute, no dosage adjustment is needed.</p>
          </list-item>
          <list-item>
            <p>Naproxen is not recommended&#x000a0;for patients with CrCl less than 30 mL/min.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25522.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Primary adverse effects for naproxen include dyspepsia, nausea, dizziness, elevated liver enzymes, increased blood pressure, diminished renal function,&#x000a0;rash, increased bleeding risk, and GI ulcers. Serious but rare adverse effects include blood dyscrasias, Stevens-Johnson syndrome, myocardial infarction, stroke, heart failure, and anaphylaxis. The following are several mechanisms of the above adverse effects:</p>
        <p><bold>GI Effects<italic toggle="yes">:</italic></bold> COX-1 and COX-2 inhibition lead to decreased prostaglandin synthesis in the gastric mucosa. The prostaglandins maintain mucosal integrity, therefore decreased synthesis causes&#x000a0;reduced protection to the tissue. However, studies indicate COX-1 has a more significant effect on the integrity of the mucosa; consequently, selective COX-2 inhibitors such as Celecoxib do not have as much of an effect on gastric tissue.<xref ref-type="bibr" rid="article-25522.r8">[8]</xref><xref ref-type="bibr" rid="article-25522.r9">[9]</xref></p>
        <p><bold>Renal Effects<italic toggle="yes">:</italic></bold>&#x000a0;Prostaglandins produced by both COX-1 and COX-2 are important regulators of renal function, hemodynamics, and sodium and water reabsorption in the kidneys. When renal blood flow is dependent upon prostaglandin synthesis, NSAID administration can significantly decrease renal blood flow, leading to acute kidney injury and renal failure. Also, alterations in sodium and water reabsorption may increase blood pressure, especially in patients with pre-existing hypertension.</p>
        <p><bold>Platelet Effects<italic toggle="yes">:</italic></bold>&#x000a0;Platelet aggregation&#x000a0;inhibition with naproxen is due to the dose-dependent inhibition of COX-1 in platelets. This action leads to decreased levels of platelet thromboxane A2 and an increase in bleeding time. This inhibition is reversible upon discontinuation of naproxen. Despite the known inhibition of platelet function, studies examining an increase in clinical bleeding time have shown mixed results.<xref ref-type="bibr" rid="article-25522.r10">[10]</xref></p>
      </sec>
      <sec id="article-25522.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Documented hypersensitivity to NSAID medications</p>
          </list-item>
          <list-item>
            <p>ASA or NSAID-induced asthma</p>
          </list-item>
          <list-item>
            <p>Pregnancy (caution against use&#x000a0;in 1st trimester, absolute contraindication at 30 weeks gestation)</p>
          </list-item>
          <list-item>
            <p>Perioperative use for coronary artery bypass graft surgery (CABG)</p>
          </list-item>
        </list>
        <p>
<bold>Relative Risk/Caution Against Using</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Recent MI or history of heart disease</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Fluid retention/edema</p>
          </list-item>
          <list-item>
            <p>Dehydration</p>
          </list-item>
          <list-item>
            <p>History of GI adverse events (peptic ulcer disease, GERD)</p>
          </list-item>
          <list-item>
            <p>Bleeding or coagulopathy conditions</p>
          </list-item>
          <list-item>
            <p>Hepatic disease</p>
          </list-item>
          <list-item>
            <p>Renal disease</p>
          </list-item>
          <list-item>
            <p>Asthma</p>
          </list-item>
          <list-item>
            <p>Sodium restrictions</p>
          </list-item>
          <list-item>
            <p>Chronic alcohol use</p>
          </list-item>
          <list-item>
            <p>Tobacco use</p>
          </list-item>
          <list-item>
            <p>Elderly/geriatric patients</p>
          </list-item>
          <list-item>
            <p>Females actively trying to conceive</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25522.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients taking naproxen should receive monitoring for pain relief,&#x000a0;significant changes in&#x000a0;blood pressure, worsening kidney function, and GI symptoms such as gastroesophageal reflux disease (GERD), abdominal pain, or melena. For patients on chronic NSAID therapy,&#x000a0;periodic monitoring with complete blood counts to assess for anemia and chemistry panels to evaluate kidney and liver function merit consideration.<xref ref-type="bibr" rid="article-25522.r11">[11]</xref></p>
      </sec>
      <sec id="article-25522.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Naproxen overdose is common due to its OTC availability, but the overdose is usually mild in severity, and serious adverse effects from overdose are rare. There is no available antidote for naproxen overdose; however, monitoring vital signs and supportive care is recommended. The role of activated charcoal is uncertain due to time constraints and unclear benefits, and there is no role for hemodialysis due to naproxen's high degree of&#x000a0;protein binding.&#x000a0;However, ingestion of large amounts of Naproxen can lead to severe toxicity causing seizures and metabolic acidosis, which can potentially cause renal failure. Therefore, although hemodialysis is not generally recommended, it can correct acid-base disturbances and provide additional support to those with renal impairment in specific situations.<xref ref-type="bibr" rid="article-25522.r12">[12]</xref></p>
      </sec>
      <sec id="article-25522.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Naproxen is readily available OTC and widely used for pain relief for many different types of&#x000a0;patients. Some of these patients take medications or have medical comorbidities that place them at a significantly higher risk of serious adverse events. Yet, they are unaware of the risk and may think that&#x000a0;naproxen's availability OTC means its use is safe for everyone. It is essential for all interprofessional healthcare team members&#x000a0;who work in a primary care setting to routinely ask their patients whether they are taking OTC medications and educate them about the potential risks and benefits of NSAIDs, particularly related to their specific medical histories and conditions. It is also crucial for specialist healthcare providers to communicate with primary care providers, nurse practitioners, and pharmacists when starting medication or to treat a patient for a condition in which NSAID therapy is not advised or contraindicated. Providers should also educate their patients about their medical condition and how it affects their ability to take a widely available OTC medication. These interprofessional team activities will increase therapeutic effectiveness and help prevent unwanted adverse effects. [Level 5]</p>
      </sec>
      <sec id="article-25522.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25522&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25522">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25522/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25522">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25522.s11">
        <title>References</title>
        <ref id="article-25522.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ong</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lirk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>An evidence-based update on nonsteroidal anti-inflammatory drugs.</article-title>
            <source>Clin Med Res</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-34</page-range>
            <pub-id pub-id-type="pmid">17456832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Biologic effects of nonsteroidal anti-inflammatory drugs.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>1997</year>
            <month>May</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>178</fpage>
            <page-range>178-82</page-range>
            <pub-id pub-id-type="pmid">9204251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>C</given-names>
              </name>
              <collab>American Academy of Neurology</collab>
              <collab>American Headache Society</collab>
            </person-group>
            <article-title>AAN/AHS update recommendations for migraine prevention in adults.</article-title>
            <source>Am Fam Physician</source>
            <year>2013</year>
            <month>Apr</month>
            <day>15</day>
            <volume>87</volume>
            <issue>8</issue>
            <fpage>584</fpage>
            <page-range>584-5</page-range>
            <pub-id pub-id-type="pmid">23668450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gim&#x000e9;nez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pujol</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Sol&#x000e0;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Contreras-Rodr&#x000ed;guez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Deus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Soriano-Mas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Llorente-Onaindia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Monfort</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Naproxen effects on brain response to painful pressure stimulation in patients with knee osteoarthritis: a double-blind, randomized, placebo-controlled, single-dose study.</article-title>
            <source>J Rheumatol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>2240</fpage>
            <page-range>2240-8</page-range>
            <pub-id pub-id-type="pmid">25274897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gargallo</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sostres</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lanas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prevention and Treatment of NSAID Gastropathy.</article-title>
            <source>Curr Treat Options Gastroenterol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>398</fpage>
            <page-range>398-413</page-range>
            <pub-id pub-id-type="pmid">25209136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suthisisang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Poolsup</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Suksomboon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lertpipopmetha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tepwitukgid</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine.</article-title>
            <source>Headache</source>
            <year>2010</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>808</fpage>
            <page-range>808-18</page-range>
            <pub-id pub-id-type="pmid">20236345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Law</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Naproxen with or without an antiemetic for acute migraine headaches in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2013</year>
            <month>Oct</month>
            <day>20</day>
            <volume>2013</volume>
            <issue>10</issue>
            <fpage>CD009455</fpage>
            <pub-id pub-id-type="pmid">24142263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pellicano</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal damage by non-steroidal anti-inflammatory drugs: updated clinical considerations.</article-title>
            <source>Minerva Gastroenterol Dietol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>255</fpage>
            <page-range>255-61</page-range>
            <pub-id pub-id-type="pmid">25384803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gudis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sakamoto</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The role of cyclooxygenase in gastric mucosal protection.</article-title>
            <source>Dig Dis Sci</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>50 Suppl 1</volume>
            <fpage>S16</fpage>
            <page-range>S16-23</page-range>
            <pub-id pub-id-type="pmid">16184416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schafer</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Effects of nonsteroidal anti-inflammatory therapy on platelets.</article-title>
            <source>Am J Med</source>
            <year>1999</year>
            <month>May</month>
            <day>31</day>
            <volume>106</volume>
            <issue>5B</issue>
            <fpage>25S</fpage>
            <page-range>25S-36S</page-range>
            <pub-id pub-id-type="pmid">10390125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wongrakpanich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wongrakpanich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melhado</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rangaswami</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly.</article-title>
            <source>Aging Dis</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-150</page-range>
            <pub-id pub-id-type="pmid">29392089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25522.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Abri</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Pedram</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Massive naproxen overdose with serial serum levels.</article-title>
            <source>J Med Toxicol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-5</page-range>
            <pub-id pub-id-type="pmid">24756481</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
